Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 17/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 16/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dasb SCHEMBL29380613 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3TDP1 | |
| Dasb SCHEMBL29459573 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3TDP1 | |
| Dasb SCHEMBL29689760 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3TDP1 | |
| SCHEMBL32890246 | 0.83 | SLC6A4 (0.70) | SLC6A4SLC6A2SLC6A3TDP1 | |
| SCHEMBL1645160 | 0.81 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3TDP1 | |
| SCHEMBL29993160 | 0.81 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3TDP1 | |
| SCHEMBL30543447 | 0.81 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3TDP1 | |
| SCHEMBL1644204 | 0.81 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3TDP1 | |
| SCHEMBL8533846 | 0.80 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3TDP1 | |
| SCHEMBL12728082 | 0.80 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727538-A2 | NEW FORMULATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | Tactogen Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260102372-A1 | NEW FORMULATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2026-04-16 | — | — | US | disclosed |
| WO-2024259343-A2 | NEW FORMULATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2024-12-19 | — | — | WO | disclosed |
| US-20240009332-A1 | COMPOSITE EMBOLIZATION BEADS | TRANSLATIONAL AND FUNDAMENTAL TECHNOLOGIES INSTITUTE LLC | 2024-01-11 | — | — | US | disclosed |
| US-11712487-B2 | Composite embolization beads | RAIKA MEDICAL IMAGING INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20220040335-A1 | RADIOLABELED PABA AND DERIVATIVES THEREOF FOR USE AS FUNCTIONAL RENAL IMAGING AGENTS | THE JOHNS HOPKINS UNIVERSITY | 2022-02-10 | — | — | US | disclosed |
| US-20210346526-A1 | NOVEL DEUTERIUM SUBSTITUTED POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENTS AND THEIR PHARMACOLOGICAL APPLICATION | FIVE ELEVEN PHARMA INC. | 2021-11-11 | — | — | US | disclosed |
| US-11071794-B2 | Deuterium substituted positron emission tomography (PET) imaging agents and their pharmacological application | FIVE ELEVEN PHARMA INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-10912849-B2 | Deuterium substituted positron emission tomography (PET) imaging agents and their pharmacological application | FIVE ELEVEN PHARMA INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20200230263-A1 | NOVEL DEUTERIUM SUBSTITUTED POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENTS AND THEIR PHARMACOLOGICAL APPLICATION | FIVE ELEVEN PHARMA INC. (US) | 2020-07-23 | — | — | US | disclosed |
| EP-2417124-B1 | Serotonin and norepinephrine reuptake inhibitor | LILLY CO ELI (US) | 2013-12-18 | — | — | EP | disclosed |
| US-8173821-B2 | Serotonin and norepinephrine reuptake inhibitor | ELI LILLY AND COMPANY (US) | 2012-05-08 | — | — | US | disclosed |
| EP-2417124-A2 | SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR | Eli Lilly and Company (US) | 2012-02-15 | — | — | EP | disclosed |
| US-20110097274-A1 | Carbon-11 and fluorine-18 labeled radioligands for positron emission tomography (PET) imaging for the brain serotonin transporters | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-04-28 | — | — | US | disclosed |
| WO-2010117979-A2 | SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR | ELI LILLY AND COMPANY (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261762-A1 | SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR | ELI LILLY AND COMPANY (US) | 2010-10-14 | — | — | US | disclosed |
| WO-2006117218-A2 | SEROTONIN-TRANSPORT-PROTEIN BINDING RADIOPHARMACEUTICAL FOR THE PRODUCTION OF A DIAGNOSTIC MEDICAMENT FOR THE DIAGNOSIS OF HEADACHE | CHARITE UNIVERSITÄTSMEDIZIN - BERLIN (DE) | 2006-11-09 | — | — | WO | disclosed |
| EP-1519917-A4 | CARBON-11 AND FLUORINE-18 LABELED RADIOLIGANDS FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING FOR THE BRAIN SEROTONIN TRANSPORTERS | UNIV COLUMBIA (US) | 2006-05-17 | — | — | EP | disclosed |
| EP-1519917-A2 | CARBON-11 AND FLUORINE-18 LABELED RADIOLIGANDS FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING FOR THE BRAIN SEROTONIN TRANSPORTERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2005-04-06 | — | — | EP | disclosed |
| WO-2003096978-A2 | CARBON-11 AND FLUORINE-18 LABELED RADIOLIGANDS FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING FOR THE BRAIN SEROTONIN TRANSPORTERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11071794-B2 | Deuterium substituted positron emission tomography (PET) imaging agents and their pharmacological application | SLC18A2, SLC6A3, SLC6A2 | SLC6A4 4/4885SLC6A2 3/4885SLC6A3 2/4885 |
| US-20200230263-A1 | NOVEL DEUTERIUM SUBSTITUTED POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENTS AND THEIR PHARMACOLOGICAL APPLICATION | SLC18A2, SLC6A3, SLC6A2 | SLC6A4 4/4885SLC6A2 3/4885SLC6A3 2/4885 |
| US-20210346526-A1 | NOVEL DEUTERIUM SUBSTITUTED POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENTS AND THEIR PHARMACOLOGICAL APPLICATION | SLC18A2, SLC6A3, SLC6A2 | SLC6A4 4/4885SLC6A2 3/4885SLC6A3 2/4885 |
| US-10912849-B2 | Deuterium substituted positron emission tomography (PET) imaging agents and their pharmacological application | SLC18A2, SLC6A3, SLC6A2 | SLC6A4 4/4885SLC6A2 3/4885SLC6A3 2/4885 |
| US-20110097274-A1 | Carbon-11 and fluorine-18 labeled radioligands for positron emission tomography (PET) imaging for the brain serotonin transporters | SLC6A4, SLC18A2, SLC6A2 | SLC6A4 1/4885SLC6A2 3/4885SLC6A3 6/4885 |
| US-20100261762-A1 | SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR | SLC6A2, SLC6A4, TPH1 | SLC6A4 2/4885SLC6A2 1/4885SLC6A3 4/4885 |
| US-20220040335-A1 | RADIOLABELED PABA AND DERIVATIVES THEREOF FOR USE AS FUNCTIONAL RENAL IMAGING AGENTS | PABPC1, HNRNPAB, HNRNPA1 | SLC6A4 3948/4885SLC6A2 3600/4885SLC6A3 3496/4885 |
| US-20260102372-A1 | NEW FORMULATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | SLC6A4, SLC6A2, SLC6A3 | SLC6A4 1/4885SLC6A2 2/4885SLC6A3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.